This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk07: Good afternoon, ladies and gentlemen. Thank you for joining today's Teladoc Health Q4 earnings call. My name is Tia, and I will be your moderator for today's call. All lines will be muted during the presentation question of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star 1 on your telephone keypad. Also, please limit your questions to one question and one follow-up. I would now like to pass the call over to Patrick Seely, Head of Investor Relations. Please proceed.
spk11: Thank you, and good afternoon. Today, after the market closed, we issued a press release announcing our fourth quarter and full year 2023 financial results. This press release and the accompanying slide presentation are available in the Investor Relations section of the teladochealth.com website. On this call to discuss the results are Jason Gorevich, Chief Executive Officer, and Mala Murthy, Chief Financial Officer. During this call, we will also discuss our forward outlook, and our prepared remarks will be followed by a question and answer session. Please note that we will be discussing certain non-GAAP financial measures that we believe are important in evaluating Teladoc Health's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release that is posted on our website. Also, please note that certain statements made during this call will be forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause the actual results for Teladoc Health to differ materially from those expressed or implied in this call. For additional information, please refer to our cautionary statement on our press release and our filings with the SEC, all of which are available on our website. I would now like to turn the call over to Jason.
spk14: Thank you, Patrick, and thanks everyone for joining us. As we start 2024, we're very much in a time of transition as an economy, an industry, and a company. Teladoc Health has made significant strides in our increased focus on bottom-line performance, realizing more benefits of scale over the past several quarters. This year, we'll continue to accelerate that progress. Our success is evident in our most profitable year to date, delivering 33% growth in Adjusted EVA-DOT and free cash flow of $194 million in 2023. We also closed out 2023 with a strong selling season that yielded double-digit bookings growth over the prior year. The breadth of our product portfolio continued to drive cross-selling as approximately 75% of our bookings were upsells or expansions with existing clients. This is representative of our success driving increased product penetration through our large installed base of nearly 90 million virtual care members. This year, we will grow our Adjusted EVA-DOT margins and free cash flow while making continued investments in innovation. We'll do this by both growing our revenue and removing more than $85 million in expenses through efficiencies and restructuring. We're targeting 50 to 100 basis points of annual margin expansion over the next three years and have line of sight to at least $425 million of Adjusted EVA-DOT in 2025. This puts us in a strong financial position as others in the space struggle, and it provides us the flexibility to have all options on the table, including continued investments in organic innovation, tuck-in M&A, retiring debt, and giving back money to our investors through share repurchase. At the same time, we will continue to grow our top line. With approximately 90 million members and thousands of clients around the world, we continue to be the leader in whole-person virtual care. We're excited to bring to market a broader range of services in areas like weight management and pediatrics this year, even as we work to achieve profitability. And our productivity initiatives mean we will continue to invest in our leading technology and engagement capabilities. With that framing for where we are and where we're going, I'd like to quickly walk you through our Q4 results, our 2024 guidance, and our ongoing organizational review as key milestones in this journey. First, fourth quarter results. On the top line, our consolidated revenue grew 4% on a -over-year basis in the fourth quarter to $661 million. Consolidated adjusted EBITDA of $114 million grew 22% -over-year, representing 260 basis points of -over-year margin expansion to 17.3%. Revenue from our integrated care segment was in line with our expectations, growing 8% -over-year to $384 million. Segment margins expanded 230 basis points over the prior year's fourth quarter to 14.6%, a benefit of operating leverage and improved efficiency. Including the strong fourth quarter margin results, the integrated care segment delivered over 320 basis points of margin expansion and 42% growth and adjusted EBITDA for the full year. Turning to the better help segment, revenue was $276 million in the fourth quarter, while adjusted EBITDA was $58 million. Better help margins expanded 210 basis points over the prior year's fourth quarter, which helped drive -over-year adjusted EBITDA growth of 11% despite lower revenue. While we're pleased to deliver double-digit adjusted EBITDA growth at better help both the quarter and the full year, revenue and margins were below our expectations in the quarter as we saw lower yields on marketing spend. Specifically, we experienced returns on our social media advertising spend that were below target in the second half of the year, which was a departure relative to the first half. We'll speak to guidance in a moment, but our better help outlook assumes the lower yields experienced in certain channels in the second half of 2023 will persist and as a result will impact our -over-year growth rates in the first half of 2024. I'd like to take a step back and spend a few minutes providing a higher level framework for how we're thinking about our long-term outlook. I'll begin with the integrated care segment. At a high level, roughly half of our integrated care segment revenue is derived from our virtual care business, including what you may think of as our traditional Teladoc general medical business. From a business model perspective, the beauty of our virtual care business is that it's a very stable asset that provides a steady source of revenue and a large client base with approximately 90 million members into which we sell additional products and services. At the same time, it's important to remember that most US healthcare consumers have access to virtual urgent care today, so it's largely a replacement market at this point. We've consistently taken share in this market and we expect to continue to do so, but it's fairly well penetrated and accordingly, we anticipate revenue growth from our US virtual care products will be in the low single digits going forward. So think of roughly half of the integrated care segment as stable but lower growth. The remaining half of integrated care segment revenue is primarily comprised of our chronic care suite of products and our international virtual care business. Our general medical virtual urgent care book of business, including our 90 million members, represent a long runway for continued cross-selling of our chronic care products as we execute against our land and expand strategy. And when I look at our suite of chronic care products, only about 16% of our general medical client base has access to one or more of our chronic care products today. That's up from just 12% two years ago. While we've made a lot of progress over the last two years with 16% penetration, there's still a long runway for chronic care growth within our existing virtual care book. So we've been successful in selling our chronic care products through our existing client book and that gives us a lot of confidence that we can deliver mid to high single digit average chronic care revenue growth over the next few years. Our international B2B business continues to be a steady contributor to revenue growth and our expanded presence in Canada this year gives us good visibility into 2024 revenue growth. So combined, we have a reliably stable asset in our virtual care book of business and a product care suite of products and an international channel, each growing at a higher rate. Altogether, we expect mid single digit annual revenue growth for the integrated care segment over the next three years. We also see significant opportunities for margin expansion in the integrated care segment from both operating leverage and productivity improvements, all while maintaining robust capacity for sustained strong investment and long-term innovation and growth. We expect this segment will drive the majority of consolidated margin growth over the next three years. Turning now to our outlook for better health. As we step back and think about the better health segment going forward, I think of three broad growth drivers. First, overall demand for mental health services continues to rise and with significant unmet need, that demand is outpacing supply. Second, consumer preference for mental health services continues to shift toward the virtual modality. That continues to tailwind. At the same time, with our increased focus on profitable growth, as a direct to consumer business, better health's new member acquisition is gated somewhat by the amount of capital we can deploy at an acceptable rate of return in any given time period. This means better health's growth is in part dependent on our ability to efficiently reach new individuals to create awareness for better health services and convert them to members. At its current size and scale, we believe better health is by far the largest direct to consumer virtual therapy provider in the market today. Better health scale and experience affords us the unique advantage of deploying a large amount of capital efficiently each year while driving strong free cash flow. The good news is, given the continued runway for growth and our well-established algorithm for deploying advertising dollars, we believe we can drive steady growth in this business at an attractive margin. We're also increasing our focus on growing better health outside the U.S. Roughly 15% of better health's fiscal year 2023 revenue was generated in international markets, primarily in English-speaking countries such as Canada and the U.K., and we're actively working to expand better health's presence internationally. To advance this goal and accelerate better health's revenue growth internationally, we recently hired a new leader. We think there's a lot of untapped potential outside the U.S. and expect to see these efforts begin to contributing to our financial results more conveniently as we move through 2024, particularly in the second half of the year. We will continue to grow better health responsibly with an eye toward maintaining the attractive margin and free cash flow profile of the business. With over $1.1 billion in revenue and our increased focus on bottom line performance, we believe we can efficiently deploy capital to drive new customer acquisition and revenue growth at better health in the low single-digit range over the next three years with opportunities for modest margin expansion. Before I update you on the results of our ongoing operational review, I want to reinforce our commitment to investing in technology and the long-term growth of our company. Our ability to effectively leverage data and technology to drive engagement and multi-product utilization is fundamental to delivering better outcomes and lower costs for our clients. Our engagement capabilities underpinned by the data and data science remain a key competitive advantage. Therefore, it's important that we continue driving greater differentiation through investments in technologies such as machine learning and AI, improving our ability to engage with members on a hyper personalized basis. So while we continue to work hard to drive productivity and efficiency across the organization, you should expect us to continue to make sizable targeted investments in product, technology, and data. At the same time, we have increased our focus on efficiency and bottom line performance. We're driving sustained margin improvement and increased cash flow generation while continuing to make substantial investments in innovation. To date, we have identified actions that we expect will result in approximately $85 million in total annual run rate operating expense savings by the end of 2024. These savings build on the cost initiatives we delivered upon in 2023 and are expected from productivity initiatives including automation and internal process improvements, organizational realignment, and third party spend reduction. We expect $35 million of these identified cost savings to benefit 2024 adjusted EBITDA and $43 million in total impact to 2024 gap expenses inclusive of stock-based compensation. Our efforts to unlock productivity improvements are ongoing and we will provide updates as appropriate. These productivity and efficiency initiatives will allow us to drive near term growth and invest in future growth opportunities while also continuing our path toward enhanced bottom line performance and free cash flow generation. The long-term fundamentals of our business are strong and we remain committed to expanding our leadership position in the industry. With that, I'll turn the call over to Mala to review the fourth quarter and share our forward guidance.
spk05: Thank you, Jason, and good afternoon, everyone. Fourth quarter consolidated revenue of $661 million increased 4% year over year. Fourth quarter adjusted EBITDA was $114 million, an increase of 22% year over year representing a margin of 17.3%. Full-year consolidated revenue of $2.6 billion increased 8% over the prior year while fully consolidated adjusted EBITDA increased 33% to $328 million. Full-year adjusted EBITDA margins increased 240 basis points to 12.6%. Consolidated net loss per share in the fourth quarter was 17 cents compared to a net loss per share of $23.49 in the fourth quarter of 2022. Net loss per share in the fourth quarter included amortization of acquired intangibles of 43 cents per share and stock-based compensation expense of 28 cents per share. Fourth quarter free cash flow was $93.6 million compared to $11.7 million in the fourth quarter of 2022. Full-year free cash flow was $193.7 million compared to $16.5 million in the prior year. We ended the year with over $1.1 billion in cash and cash equivalents on the balance sheet. Turning to segment results, integrated care segment revenue increased 8% year over year to $384 million in the fourth quarter growing 3% sequentially. For the full year integrated care segment revenue increased 7% to $1.5 billion. The largest contributor to 2023 integrated care growth was chronic care revenue growth. Fourth quarter integrated care adjusted EBITDA was $56 million, an increase of 28% over the fourth quarter, representing a 230 basis point margin extension. During the fourth quarter, member enrollment in chronic care programs grew by 36,000 bringing full-year net enrollment growth to 139,000. We ended the fourth quarter with chronic care enrollment of $1.16 million, an increase of 14% year over year and 3% sequentially. The biggest drivers of new chronic care enrollment in fiscal year 2023 were hypertension followed by our diabetes prevention and weight management programs. As of year end, diabetes management comprised approximately half of chronic care program enrollment followed by hypertension at 30% and diabetes prevention and weight management both approximately 10% of total program enrollment. Program enrollment growth continues to benefit from our success in selling bundled chronic care management solutions. Total integrated care segment membership ended the year at 89.69 members. Average integrated care revenue per US member of $1.42 decreased 2 cents over the prior year's fourth quarter. Excluding the impact of new virtual care members added during the year, revenue per member increased 6 cents. Turning to better health, revenue was $276 million in the fourth quarter, roughly flat versus the prior year and down 3% sequentially. Fourth quarter better health adjusted EBITDA was $58 million, representing growth of 11% over the prior year's fourth quarter. Adjusted EBITDA margin of .2% increased 210 basis points over last year's fourth quarter. Better health revenue for the full year was $1.1 billion, an increase of 11% over the prior year. Full year adjusted EBITDA grew 19% over the prior year to $136 million, representing a margin of 12% compared to .2% in the prior year. Now turning to forward guidance. We expect full year 2024 revenue to be in the range of $2.635 to $2.735 billion, which represents year over year growth of approximately 1.5 to 5%. The 2024 revenue outlook includes low to mid single digit growth in our integrated care segment and flat to low single digit growth in our better health segment. We expect full year 2024 consolidated adjusted EBITDA to be in the range of $350 to $390 million, representing year over year growth between 6.7 and 18.9%. Consolidated guidance includes a year over year increase to adjusted EBITDA margin of 150 to 250 basis points for the integrated care segment and margin for the better health segment of flat, plus or minus 50 basis points. We expect full year free cash flow of $210 to $240 million, representing year over year growth of 8 to 24%. Full year stock based compensation is expected to be approximately $180 million, representing a decline of approximately $20 million. For the first quarter, we expect revenue to be in the range of $630 to $645 million. The first quarter integrated care segment year over year revenue growth is expected to be in the range of 5 to 7%, while better health segment revenue growth is expected to be down 6 to down 3% compared to the first quarter of last year. First quarter consolidated adjusted EBITDA is expected to be in the range of $52 to $62 million. First quarter adjusted EBITDA guidance includes integrated care segment adjusted EBITDA margins in the range of 10.5 to 12%, and better health adjusted EBITDA margins between 5.5 and 6.5%. One thing I want to call out related to our 2024 guidance is that we did experience a delay in launching our B2B consumer engagement efforts during the first quarter due to a technical issue in mapping new client populations. While we have fixed the issue and relaunched our marketing campaigns, we expect the cumulative effect of this one time delay to have an impact on 2024 revenue of approximately $20 million. This $20 million impact represents approximately 140 basis points of year over year integrated care segment growth, which is reflected in our 2024 integrated care segment outlook. Looking beyond 2024, as reflected in today's press release, we are also providing a long-term outlook as follows. We expect consolidated annual revenue growth over the next three years in the low to mid single digits, which includes annual growth of mid single digits for the integrated care segment and low single digits for the better health segment. We are targeting 50 to 100 basis points of margin expansion annually over the next three years and at least $425 million of adjusted EBITDA in 2025, inclusive of the identified cost actions discussed earlier. We anticipate margin expansion to be driven in large part by operating leverage over our technology and development and GNA line items. We expect annual decline since stock-based compensation over the next three years as we manage our compensation expense and march towards gap profitability, including an approximate $20 million year over year decline in 2024. Finally, with $1.1 billion in cash on our balance sheet and our business generating strong and increasing amounts of free cash flow, I thought it would be helpful to remind you of our capital allocation priorities going forward. One, TEC and M&A. We believe our large base of clients with 90 million members gives us a unique ability to bring new products to our existing book of business. We will therefore continue to look for opportunities to expand our capabilities. Two, debt pay down. We have a convertible bond due in 2025 and the cash on our balance sheet allows us the flexibility to retire that issuance if we choose. Three, share buybacks. The level of annual free cash flow we are generating will increasingly provide us the flexibility to do strategic share buybacks as well as minimize potential dilution from employee stock grants. With that, I will turn the call back to Jason.
spk14: Jason Thank you, Mala. With that, I think we will open it up for questions.
spk07: Operator? Operator We will now begin the Q&A session. If you would like to ask a question, please press star followed by 1 or your touchtone keypad. If for any reason you would like to remove that question, please press star followed by 2. Again, to ask a question, press star 1. Please limit your question and follow-up. As a reminder, if you are using a speakerphone, please remember to pick up your handset before asking your question. We will pause here briefly to allow questions to generate and kill. The first question comes from the line of Lisa Hill with JP Morgan. Please proceed.
spk08: Lisa Hill Thanks very much and thanks for all the detail. Jason, I just want to go back and talk for a minute about the selling season and try to square just a couple of numbers that you gave and Mala gave. Mala talked about chronic members being up 14%. You talked about double-digit booking growth and the selling season. Yet, when you talked about the integrated business and talked about the chronic component of that, you talked about mid to high single-digit growth. Can you help me to understand, is it that you are doing more bundled programs and therefore the growth is not as high? Secondly, as we think about this going forward, you talked about 16% of the base having access. Is this an opportunity where 100% of your base can have access or is it some smaller number as I think about that? Jason, I just want to ask you a question that I think is a little bit more complex than the one that I just asked. What would be my question?
spk14: Jason Hickman Thanks Lisa. I appreciate the question. As we think about our longer term outlook, we do think that we'll continue to penetrate our book of business with our chronic care programs. As we've said, about 75% of our sales came from selling to existing clients. As we make progress and we made progress over the last two years from 12% to 16% penetration, we think that we will continue that progress. As I went through the bookings last year and then think about that versus this year, as we discussed in the prepared remarks, we had this temporary mapping issue with new member onboardings and that caused us to pause marketing for about three weeks. That has an impact of about $20 million or about 140 basis points of integrated care growth, almost all of which is centered on our chronic care programs. As you think about growth in chronic care this year, the vast majority of that impact is on our chronic care programs. The second thing to think about for this year is as we booked business in sales last year, there's always a timing question of when those sales go live and produce revenue. We did have a meaningful amount that came through of in-year revenue with starts last year. We do have some that is going to start not in January, but actually starts in the late first beginning of second quarter. That's factored into the full year revenue outlook and therefore the growth that comes along with it. We do think that chronic care revenue will continue to be the driver of higher levels of growth and integrated care, especially as you consider it relative to that very stable book of virtual care revenue. The good news about that is it provides us the base into which we sell. As you pointed out, we do see more and more bundled programs being sold. As we talked about at your conference, actually, when we sell a bundle of services, we tend to get higher revenue, but lower revenue per member than when we sell individual products. We get higher revenue per client for the entire population, but lower revenue per member than when we sell on sort of an a la carte basis, so to speak. When you put all of that together, we feel good about the multi-year outlook of chronic care and international for that matter being drivers of our integrated care revenue growth.
spk06: Thank you. The next
spk07: question comes from Delana Stephanie Davis with Barclays. Please proceed.
spk04: Hey guys, thank you for taking my question. Apologies for my background noise. I was hoping you could talk me through some of your assumptions getting to the better health outlook. What improved and underlined assumptions? Is there any color you can provide about the tear gating yields and if it's improved? Just in general, how much risk is baked into the outlook, such as macro assumptions?
spk14: Stephanie, I'll start and then Mala can go deeper. On better health, if you think back to our third quarter earnings call, we talked about how customer acquisition cost trends in the direct to consumer market would result in better health growth in the lower half of our guidance range. Our original 23 outlook called for double digit to mid teens growth for better health. That range assumed some deterioration at the low end of the range and some improvement at the high end of the range. Better health ended up growing just over 11% for the full year. So it was in the lower part of our guidance range. What drove that was weaker customer acquisition trends in the second half of the year. There are a bunch of factors that go into that. In particular, we saw pressure on our customer acquisition costs in social media channels. We're fortunate. I guess the good part is we have a diversified set of channels and the higher overall spend levels as we get to higher levels, the more we press on sort of across all of those channels. So we felt the impact of that in the second half of the year as we made our outlook for this year in 2024. The assumption is that those higher levels of customer acquisition costs persist. We do think that we'll start to get a benefit in the back half of the year from some of our international markets as we shift dollars into those international markets, which we've seen good results, but at a limited scale thus far. The customer acquisition costs tend to be lower in the international markets, although the cost of goods sold tends to be slightly higher. If you balance those two things, they end up at roughly the same net margin as our domestic business. So when we look at the range for our outlook, it sort of brackets that current outlook, meaning if you extend the current situation forward, the lower end of the guidance assumes that there's some deterioration. The higher end of the guidance assumes some improvement.
spk05: Yeah, I think you've covered most of it, Jason. What I would say, Stephanie, is we believe we've taken a measured approach to our guidance by assuming that the levels of cost per acquisition trends continue as we saw in the back half and frankly, as we are continuing to see in the first quarter of this year. So, as Jason said, if you think about the range we have provided at the high end of the guidance range, we assume some improvement in customer acquisition trends in the second half and at the low end of the range, we assume some deterioration in those trends. And as we said in our prepared remarks, if you sort of take a step back and just think about the Better Health business, what I would also say is, with our increased focus on profitable growth, the Better Health business's new member acquisition is somewhat gated by the amount of capital we can deploy at what we would consider to be acceptable rates of return during any given period. So, what that means is that the growth in Better Health is in part dependent on our ability to efficiently reach new individuals to create awareness for Better Health products and services. So, it is both, I would say, the cost per acquisition trends that we are seeing that we have factored into our business, into our guidance and a continuing theme of how we are balancing top line growth with profitability in this business.
spk14: And it's probably evident from our comments, but it's worth calling out that with pressure on customer acquisition costs in the back half of 23, the second half of 24 will be comped against that. And so, actually has a, the first half has a more challenging comp, the back half has a lower bar.
spk06: Thank
spk07: you. The next question comes from the line of Helendra Singh with Truist Securities. Please proceed.
spk01: Hi, this is Helendra Singh from Truist. Thanks for taking my questions. So, just wanted to follow up on the question on the, on the efficiency program, like 35 million benefit in EBITDA. It seems more than half of that is coming in Q4. Can you help us better understand why benefit from this program is more second half loaded? Are you expecting any benefit in Q1? And how is this benefit spread across two segments?
spk05: Yeah, so I would say on your second question, Helendra, most of the benefit of these cost efficiency and cost takeout programs is really on the integrated care side. As we said in our prepared remarks, the integrated care side is where we will see more of margin expansion as we go through the year. You know, we can drive more operating expense leverage on the integrated care side of the house. And I would say in terms of the, how the 35 million dollars of benefit accrues this year on an adjusted EBITDA basis, 43 million obviously on a gap basis. Look, we are taking initiative, we are doing initiatives across a number of different areas, whether it be organizational improvements, including things like offshoring, whether it be productivity initiatives, including automation, or whether it be third party supplier spend. So I wouldn't say that these benefits are back and loaded into one particular quarter. We will see them ramp through the year.
spk06: Thank you. The next question comes
spk07: from the line of Richard Close with Kemicorgenuity. Please proceed.
spk10: Yes, thanks for the questions. I appreciate the details on the delayed enrollment engagement or marketing on the chronic care that you talked about and the financial impact there. But can you provide more details exactly what that was? Was that on the customer side or your side? And if it was on your side, how do you get comfortable that that's not going to happen again?
spk14: Yeah, Richard, thanks for the question. We had record client implementations for January 2024. And like all healthcare companies who deal with eligibility files, these implementations come with just an inherent amount of complexity. In January, we discovered an issue in mapping data for some of these implementations. The number of affected members turned out to be actually very small, but with a record number of implementations happening at the same time, out of abundance of caution, we halted member communications while we diagnosed and resolved the issue. The delayed consumer, this delayed our consumer engagement marketing by about three to four weeks and pushes out the enrollment curve for primarily our chronic care programs. And so, as we said, we anticipate that that delay ends up sort of rippling through by shifting out the curve to the tune of about 20 million for the full year. We've restarted the marketing engine and we've seen absolutely no new issues. So we're confident that the issue is completely behind us. What I would say is that it was our caution in making sure that we had the full diagnosis and scope of the issue and the affected population identified before we turned our marketing campaigns back on. And as it turns out, the scale of the affected members was actually very small. So we're confident that we have it behind us. We have clearly identified the source of the issue and actually the scale of the issue was very, very small.
spk07: Thank
spk06: you.
spk07: The next question comes from the line of Jessica Sasan with Piper Sandler. Please proceed.
spk09: Hi, guys. Thank you so much for taking the questions and thank you for the detail in the report and guide. I guess maybe just in terms of ad yield on BetterHelp, I'm curious to understand maybe when you all first observed the declining ad yield in BetterHelp and just kind of whether it was a good idea to do that. And then I'm curious to know if you had any updates on whether it got worse over the course of 2023 and any update on what you've observed year to date in 2024.
spk05: Yeah, thanks, Jess. We had actually started observing the yields coming in lower than we had expected in the back half the year. We actually had talked about it in the October 3rd quarter earnings call. We had talked about the fact that last year when we had initially given the range, we were talking about coming in at the low end of the range if we see the yields start deteriorating, being at the high end of the range if we saw improvement. And we had talked about the fact that the yields are starting to come, are lower in the back half of the year. So, as we said a few minutes ago, we have sort of kept watch over those trends. They have persisted through the back half of the year. They are still persisting and that is the reason why we have factored that into the guidance. And as Jason said, we expect to comp that in the second half of the year. The comps get easier in the second half of the year. Having said that, that's the reason we are providing the range that we are providing. Again, similar to last year, what we would say is the high end of the range assumes improvement. The low end of the range assumes a deterioration.
spk14: We generally see improvement in January. We generally see improvement in January. And so we monitored closely as we were going through the January timeframe and we saw them stubbornly, especially in those channels, stubbornly higher. And so we are using that as the basis for our guidance going forward.
spk07: Thank you. The next question comes from the line of Charles where I would see the Cowan. Please proceed.
spk02: Yeah, thanks for taking the question. Jason, I want to go back to integrated care real quick. And you may have mentioned that 16% of the general medical base has access, is one or more of the chronic care products. And that's up from 12%. I think you said over the last few years. You also may mention that 75% of your sales are from existing clients. Can you talk a little bit about what the sales pipeline looks like? And how often are these clients coming up for potential cross-sell? And I guess the question is, how often is it that people are just choosing not to make a decision? Because it seemed like you would have a large base to be selling into. But given sort of the growth rates you're talking about, it's sort of a slow, gradual improvement over time. Just try to understand the dynamics of decision making among clients to add chronic care if they don't have it already.
spk14: Yeah, thanks Charles. I'll try to answer as many of the dimensions of that question as I can. With respect to the pipeline, we're really early in the year. And generally what happens is we sell through the pipeline toward the end of the year. And at this point of the year, we're refreshing it. That's exactly what's happening now. So I'll reserve commentary on sort of what the pipeline looks like until later in the year when it refills and we're looking at our significant selling season sort of bolus. With respect to the dynamics of our client base, our sales force is broken into, split into essentially new business reps who are out trying to sign new clients who don't have a relationship with Teladoc Health. And account managers and essentially upsellers whose job is to go build our base with our existing customers. When we think about selling into new clients, there are essentially two dimensions of that. One is selling more products into the same population. The second is selling products into new populations within that client. That tends to happen mostly within health plans as we go into new geographies, new lines of business, such as managed Medicaid or Medicare Advantage. And we expand the population that we serve. So you're really asking, I think, mostly about that first one of selling into new clients or into existing clients, which is upselling additional products. We're constantly working through that. And I would say the adoption for chronic care programs goes through an evolution. Some of those clients have other solutions that they bought previously and it's a replacement business for us. Equally as frequently, we're going in with our suite of chronic care solutions where they don't have one in place. And so that is an evolutionary sale. It certainly doesn't happen all at once. So I wouldn't expect us to, you know, all of a sudden go from 16 to 30 or 40% penetration. We are working on solutions like our bundling structures in order to accelerate the penetration. But right now we guide based on what we know and what our existing trends are. So as we see breakthroughs to the degree that we see breakthroughs in our ability to more rapidly penetrate our book of business, we'll update our guidance. But our guidance right now is based on the progress that we're making and our outlook based on what we know, not based on any breakthroughs that we haven't yet identified.
spk07: The next question comes from the line of George Hill with Dasha Bank. Please proceed.
spk03: Yeah, good evening Jason and I'll try to be efficient with my questions here. And I guess my first one, Mala is on the cost savings program, which is you guys are targeting 50 to 100 basis points of margin expansion per year. But the cost savings programs alone should give you almost 150 basis points of margin expansion in 24 and over 325. So I guess I'd ask you, what are the offsets in the underlying business that are eroding when the cost savings programs don't give you more margin expansion?
spk05: Yeah, thanks, George. So if you just think about 2024, as we have said, we've talked about our guidance of 350 to 390 million in adjust to the data. That includes the 35 million of cost savings that we have talked about. You know, the reality is, if you think about the way the margins we expect in 2024, the margins to play out, we are seeing some modest pressure on our gross margin line from higher clinical costs. And that's primarily associated with the expected ramping up in primary 360 volumes. We added about 30 million dollars in primary 360 revenue over the course of 23. And that was a very, very significant increase in revenue for P360. And we expect visit volume from those members to continue to ramp up through 2024. And so that ramp will create some modest pressure on gross margins this year relative to 2023. Now, that variance, that delta is being offset by leverage from operating expenses and in particular, as we said in our prepared remarks, technology and development and GNA. So that's sort of the way the sort of the margin structure is feathering through the whole PNL.
spk06: Thank you.
spk07: The next question comes from the line of Sean Dodge with RBC Capital Markets. Please proceed.
spk15: Yeah, thanks. Last quarter, along with the operational review, you also talked about undertaking a portfolio assessment. Is there any update you can share on that? Are there any portfolio actions in the savings you laid out from the efficiency program or would those be incremental? And then maybe if you give us some sense of what a portfolio assessment may involve, are there particular geographies, markets, books of businesses that just don't make sense to be in anymore?
spk14: Yeah, so I'll start by saying there are no significant portfolio changes contemplated in our guidance. Anything that we would do would be incremental to that. When we talk about doing a portfolio assessment, it really is looking across the business for two dimensions. One, what's the profitability and growth outlook for the various customer channels and segments, products within our portfolio, geographies, etc.? And then second is where do we place investments? So, you know, where do we get the greatest yield on investing our dollars, especially in technology and development? And advertising and marketing. So, I think that's what's involved in it. If we have any significant actions, obviously we'll announce it. A lot of it, quite frankly, is fine tuning. Sometimes it's fine tuning pricing. Sometimes it's fine tuning go to market strategies. Sometimes it's fine tuning service model and service intensity to make sure that we're optimizing our resource allocation versus the profitability of a given customer segment or product.
spk05: Yeah, I would say I would add, Sean, look, as we look at our both top line growth as well as bottom line profitability, you know, we have set expectations for the next few years. We'll continue to look at the various pieces of our business, you know, how they contribute to both top line growth as well as bottom line profitability. And so that's a review that is ongoing. We will continue to look at that. And as Jason said, you know, we are judicious in the investments we make. We have talked about getting leverage from technology and development and GNA. That said, we are also going to continue to invest robustly in the business, whether it be in terms of product data, data science. And so in order for us to fuel those investments and the investment capacity, the responsible thing for us to do is to just continue to look at all parts of our business in terms of how they are contributing to both top line as well as bottom line.
spk07: Thank you. The next question comes from the line of Ryan Daniels with William Blair. Please proceed.
spk13: Thanks for all the detailed commentary thus far. Maybe a little bit of a different line of questioning. I'm just curious in regards to capital deployment. You clearly have a lot of cash. You mentioned maybe a repo, but more curious about the overall capital structure and how you view it. I know you have some of the Levongo converts of about five hundred fifty million that will become current in June and then a bigger convert a couple years after that. So how are you thinking about potential refi or use of cash to pay that down over the coming quarters? Thanks.
spk05: Yeah, thanks for that question. You know, listen, as I step back and take a look at our capital structure, we are, we have the flexibility with the billion one cash that we have on our balance sheet and the fact that we generate a strong free cash flow last year. We expect to continue to generate strong free cash flow this year, so that will certainly strengthen our balance sheet even more. If I think about the uses of cash, I would say, you know, the way I would prioritize it is, as we said first, what are the interesting M and A opportunities that are out there that we could use our balance sheet for? Obviously, as always, those M and A opportunity opportunities need to meet the criteria that we set for ourselves, right? Whether they make strategic sense for us or whether they are financially attractive. But I would expect to use the strength of our balance sheet towards the right M and A opportunities and then I would use our cash to pay down to retire the debt. Specifically, you mentioned the Lovongo convert, which is due in the middle of twenty twenty five. You know, I would look to pay that converted down. We still have some time and flexibility for the billion dollar convert that is maturing in twenty twenty seven. And then last is, as we said, to the extent that we have even more flexibility on the balance sheet, you know, opportunistically, strategically think about share buybacks. If, you know, share buybacks in general, and, you know, to think about over the longer term to offset the potential dilution from employee stock grants. So I would think about it in those sort of in those different ways.
spk06: Thank you.
spk07: The next question comes from the line of Daniel grass light with city. Please proceed.
spk12: And I go back to the better out marketing yield here. I was wondering if you could provide a little more detail on on why those marketing yields remain depressed or consumers being a little more discerning. Are you seeing more competition from other vendors? Is there another big vendor out there that's spending like, you know, twenty two? Any additional detail there would be would be very helpful.
spk14: Yeah, so it's the answer to the second part of the question is, we don't see a significant competitor driving up the rates. We do see a lot of advertisers in general going after a similar population. So I wouldn't say that it's a single competitor as opposed to the the overall traffic in the ad space, so to speak. And then maybe the last thing I'll say is that we do see it certainly more as we spend more. Right. So as we increase our ad spend, we're constantly looking at the marginal return on the on each incremental dollar. And so we we work hard to make sure that each incremental dollar is productive for us. And to the degree that we see the curve. Get to an inflection where we run out of room on where we can spend that money productively, then we pull back rather than chasing growth at the expense of profitability. So so I think those are the major contributors to it.
spk06: Thank you. There are no additional questions left at
spk07: this time. That concludes today's conference call. Thank you. You may now disconnect your line.
Disclaimer